media – Page 560 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

EKGs May Determine Major Depression or Bipolar Disorder

A groundbreaking Loyola Medicine study suggests that a simple 15-minute electrocardiogram could help a physician determine whether a patient has major depression or bipolar disorder.
- Source: bphope
- 627
- February 14, 2018
bipolar disorder Depression Researches
Could AI One Day Detect the Flu…Before You Even Feel Sick?

It’s flu season, and many of us find ourselves glancing nervously at anyone coughing or sniffling in our vicinity. But how, besides shielding ourselves from public sneezers, do we avoid coming into contact with infections?
- Source: smithsonianmag
- 627
- February 14, 2018
AI flu Market Views
Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis.1 The updated label includes Cosentyx data in moderate to severe scalp psoriasis – one of the difficult-to-treat forms of the disease, which affects approximately half of all psoriasis patients.1-3 The label update is effective in the US immediately, and is based on the proven efficacy and consistent safety profile of Cosentyx from a dedicated Phase III scalp psoriasis trial.6
- Source: pharma.us.novartis
- 552
- February 13, 2018
Cosentyx® FDA New Approvals Scalp psoriasis
Global Investors Back Rani Therapeutics With $53 Million As Company Moves To Clinical Trials

Rani Therapeutics, the developer of a pill designed to replace injectable drug delivery for patients suffering from chronic diseases, today announced that it has raised $53 million to invest in manufacturing in preparation for human clinical trials. This investment brings the total raised to $142 million in funding.
- Source: Prnewswire;
- 518
- February 13, 2018
chronic diseases Clinical Trials Series
Abbott supports Angle’s breast cancer liquid biopsy study

Healthcare firm Abbott will provide its PathVysion HER-2 DNA FISH probe kits for use in Angle's breast cancer liquid biopsy study.
- Source: invitrodiagnostics.medicaldevices-business-review
- 629
- February 13, 2018
Abbott breast cancer liquid biopsy Researches
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder

Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to SAGE-217 for the treatment of major depressive disorder (MDD). This is the second Breakthrough Therapy designation granted to Sage since 2016.
- Source: finance.yahoo
- 748
- February 12, 2018
biopharmaceutical FDA major depressive disorder New Approvals
CRISPR CSO departs as Celgene continues to sell stock

Bill Lundberg, M.D., has stepped down as CSO of CRISPR Therapeutics. News of Lundberg’s departure emerged on the same day Celgene revealed it has sold another chunk of its once-double-digit stake in the CRISPR/Cas9 gene editing startup.
- Source: fiercebiotech
- 547
- February 12, 2018
Celgene CRISPR Market Views
UK launch for Bayer’s five-year contraceptive Kyleena

A new long-acting reversible contraception method offering protection from unplanned pregnancy for up to five years has been launched in the UK.
- Source: pharmatimes
- 374
- February 12, 2018
Kyleena Researches unplanned pregnancy
ViiV kicks off PhIII trial of two-drug HIV regimen

ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
- Source: pharmatimes
- 570
- February 12, 2018
Clinical Trial HIV Phase TANGO
Risk-averse ACOs miss out on nearly $1B in savings

A vast majority of accountable-care organizations in zero-risk contracts would reap additional savings if they took on downside risk because of the bonuses incurred as an advanced alternative payment model under MACRA, a new analysis finds.
- Source: modernhealthcare
- 442
- February 12, 2018
ACOs Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.